Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

New Method Separates Cancer Cells From Normal Cells
The vast majority of cancer deaths are due to metastasis, the spread of cancer cells from its primary site to other parts of the body. These metastatic cells tend to move more than their non-metastatic variants but this movement is poorly understood. Scientists are studying cancer cells intently with the hope they can learn to control the movements of the dangerous cells.
generic viagra online
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression In Rheumatoid Arthritis Models By Selective Inhibition Of The Immunoproteasome
Proteolix, Inc. announced that in an article published in Nature Medicine, Proteolix"s selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis. Drugshop to buy zoloft online and other pills.
News of the day
DFine Europe GmbH Accepts Terms Of Preliminary Injuction Issued By German Court For Medtronic GmbH
Medtronic, Inc. announced that DFine Europe GmbH has accepted the terms of a preliminary injunction granted to Medtronic GmbH by a German Competition Court. The preliminary injunction stops DFine Europe GmbH from using certain misleading marketing claims related to Medtronic"s Kyphon® Balloon Kyphoplasty products in Germany.
Health Insurance

Continued Vigilance Against Drug-resistant Malaria Is Needed

Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups. Malaria kills more than a million people each year and accounts for more than a third of public health expenditure in some badly affected countries. Uncomplicated malaria is a mild version of the disease, but it can become serious and life threatening if left untreated. Resistance to the older antimalarials has led the WHO to recommend treatments combining an artemisinin-based drug with another longer-lasting drug to combat resistance. The review included 50 trials of artemisinin-based combination therapies (ACTs). Overall, the four combinations studied were effective for treatment of the most common type of malarial parasite. The researchers conclude that the recently introduced dihydroartemisinin-piperaquine performed well compared to the ACTs in current use and offers another potential first-line therapy for the disease. There were examples of treatment failure rates above 10% for all evaluated combinations. This is above the maximum allowable failure rate for a first line antimalarial as recommended by the WHO. "Patterns of resistance change from place to place and over time, so these results have to be interpreted with some caution," says lead researcher David Sinclair of the Liverpool School of Tropical Medicine in Liverpool, UK. "Our findings emphasise the need for continued vigilance in the monitoring of malaria and the development of resistance to antimalarial drugs." In addition, there were few studies focusing on the most at-risk groups, which are pregnant women and young infants. "The lack of evidence supporting the use of these drugs in pregnant women and infants represents a critical gap in our knowledge that must be addressed," says Sinclair. Jennifer Beal Wiley-Blackwell


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009